{"organizations": [], "uuid": "99ae31be59705ea84c6266ecfc2ac31510988752", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-vbi-vaccines-announces-positive-fi/brief-vbi-vaccines-announces-positive-final-phase-1-study-results-of-preventative-cmv-vaccine-idUSFWN1SH0RB", "country": "US", "domain_rank": 408, "title": "BRIEF-VBI Vaccines Announces Positive Final Phase 1 Study Results Of Preventative CMV Vaccine", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-10T14:31:00.000+03:00", "replies_count": 0, "uuid": "99ae31be59705ea84c6266ecfc2ac31510988752"}, "author": "", "url": "https://www.reuters.com/article/brief-vbi-vaccines-announces-positive-fi/brief-vbi-vaccines-announces-positive-final-phase-1-study-results-of-preventative-cmv-vaccine-idUSFWN1SH0RB", "ord_in_thread": 0, "title": "BRIEF-VBI Vaccines Announces Positive Final Phase 1 Study Results Of Preventative CMV Vaccine", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "vbi vaccines inc", "sentiment": "none"}, {"name": "preventative cmv vaccine reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 10, 2018 / 11:33 AM / in 7 minutes BRIEF-VBI Vaccines Announces Positive Final Phase 1 Study Results Of Preventative CMV Vaccine Reuters Staff\nMay 10 (Reuters) - VBI Vaccines Inc:\n* VBI VACCINES ANNOUNCES POSITIVE FINAL PHASE 1 STUDY RESULTS OF PREVENTATIVE CMV VACCINE\n* VBI VACCINES INC - SAFE AND WELL-TOLERATED AT ALL DOSES WITH NO SAFETY SIGNALS OBSERVED IN STUDY\n* VBI VACCINES INC - CMV NEUTRALIZING ANTIBODIES AGAINST FIBROBLAST CELL INFECTION INDUCED IN 100% OF SUBJECTS WHO RECEIVED HIGHEST DOSE IN STUDY Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-10T14:31:00.000+03:00", "crawled": "2018-05-10T14:45:52.015+03:00", "highlightTitle": ""}